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Objective: To retrospectively determine DNA levels in  blood polymorphonuclear leukocytes (PMNLs) of 21 heart 
transplant patients who suffered from HCMV infection and who were monitored by the antigenemia assay (pp65 test) 
during follow-up, by use of a quantitative competitive polymerase chain reaction (PCR) assay for human cyto- 
megalovirus (HCMV) DNA. 
Methods: Quantitation of HCMV DNA by PCR was expressed as genome equivalents (GE) per 200000 PMNLs. 
Results: Ten patients experienced symptomatic HCMV infection (five primary infections and five reactivations) with 
mild symptoms and received ganciclovir treatment, whereas 11 asymptomatic HCMV infections were not treated. 
Therapy was discontinued when a 90% reduction of the pretreatment antigenic load was achieved in a symptomless 
patient. The mean HCMV DNA and antigenic loads were significantly higher in  symptomatic than in asymptomatic 
patients: 4 . 6 ~ 1 0 ~ f 4 . 7 ~ 1 0 ~ G E  and 1 . 1 ~ 1 0 ~  GE (p<O.OOOl) and 390k350 versus 2 5 i 1 2  pp65-positive PMNLs (p<O.OOOI), 
and in  primary than in secondary infections (583i403 pp65-positive PMNLs versus 85+ 111, p=0.002 and 
5.2y105k5.2r105 GE instead of 1.5x1O5?3.2r1O5 GE, p=0.02). A single course of 14-21 days of ganciclovir caused a 
marked decrease of HCMV DNA and antigenemia in  eight of 10 patients in whom a 90% reduction of the antigenic load 
correlated with a 98% DNA reduction of the pretreatment levels. In two primary infections, a 90% antigenic reduction 
was achieved by 21 days of ganciclovir treatment, but those data only correlated with a DNA load reduction of 28% and 
60% of the pretreatment levels. Fifteen and 12 days later, respectively, the two patients relapsed and underwent a second 
ganciclovir course, at the end of which a 90% reduction of the antigenic load correlated with a >98% DNA drop. GCV 
was discontinued and the patients recovered completely. In those two patients we retrospectively found persistent high 
DNA levels before the second ganciclovir course, whereas the antigenic load slowly increased after an apparent reduction. 
Conclusions: Our data suggest that: (1) DNA levels have the same trend as the pp65 antigen test-they are significantly 
higher in  symptomatic and in primary HCMV-infected patients than in asymptomatic patients and those with secondary 
infection; (2) a 90% antigenic load reduction from the pre-treatment level may be a less reliable predictor of the efficacy 
of anti-HCMV therapy than DNA load, at least in primary infection, in  which a much higher viral load and much more 
severe disease are present; and (3) a DNA load reduction of >98% of the pretreatment value is required for therapeutic 
success. 
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INTRODUCTION 
Human cytomegalovirus (HCMV) is a well-known 
cause of morbidity and mortality in heart transplant 
(HT) patients [l-81. With the introduction of effective 
anti-HCMV therapies such as ganciclovir and foscarnet 
[9,10], early diagnosis and pre-emptive therapy are 
essential for proper management of the infection. New 
parameters and procedures for prompt diagnosis as 
well as for careful monitoring of HCMV infection 
have been developed. Polymorphonuclear leukocytes 
(PMNLs) are the major HCMV carriers among white 
blood cells during active HCMV infection, and 
detection of the HCMV lower matrix phosphoprotein 
pp65 in PMNLs is an early marker of HCMV infection; 
the number of pp65-positive PMNLs correlates with 
the development of clinical symptoms in transplant 
patients [ll-171. The polymerase chain reaction (PCR) 
has proved to be a powerful method in diagnostic 
virology. Because of its high sensitivity, P C R  may be 
used to detect HCMV in blood earlier than antigenemia, 
as well as for HCMV tissue localization and for 
monitoring anti-HCMV treatment [ 18-30]. However, 
quantitative P C R  has given results of variable clinical 
relevance in HCMV infection [21-251. In recent years, 
major advances have been made in HCMV DNA 
quantitation, either by P C R  [26-361 or by hybridiza- 
tion techniques [37-391. Published data that compared 
antigenemia and/or viremia and quantitative deter- 
mination of HCMV DNA showed that non-PCR 
hybridization methods were less sensitive than P C R  
and antigenemia, but their results correlated with 
clinical symptoms better than qualitative PCR [37-391. 
Quantitative P C R  (qPCR) for HCMV DNA could 
be used to differentiate low from high viral load in 
blood, a high load being correlated with subsequent 
development of HCMV disease, and for anti-HCMV 
therapy monitoring. qPCR seems to be promising for 
monitoring HCMV infection in immunocompromised 
patients [26-361 but it is a highly complex technique 
and further studies are required to assess its clinical 
relevance. 
In the present study, we quantitated HCMV DNA 
retrospectively by P C R  in the PMNLs of a study 
group of 21 HT recipients who suffered from HCMV 
infection. These patients were also prospectively 
monitored for HCMV infection by the antigenemia 
assay (pp65 antigen test), and we compared the quan- 
titative detection of pp65 antigen in the PMNLs to the 
DNA load detected by PCR. We concentrated on 
qPCR results with regard to the early identification of 
ongoing HCMV infection, the correlation with the 
development of clinical disease and monitoring antiviral 
treatment. 
MATERIALS AND METHODS 
Patients 
The study group consisted of 21 of 135 patients who 
underwent orthotopic heart transplantation from January 
1993 to January 1997 at the Cardiac Surgery Depart- 
ment of the University of Turin, Italy, and who had 
either symptomatic or asymptomatic HCMV infection 
in the early post-transplant period. All patients were 
prospectively monitored for HCMV infection on the 
basis of the antigenemia assay. HCMV DNA was 
retrospectively quantitated in the PMNLs in patients 
with either symptomatic or asymptomatic infection. 
The 31 patients of this study were the transplant 
patients who had had positive antigenemia and whose 
blood leukocytes were available for retrospective analysis. 
All patients were given a triple immunosuppressive 
regimen of prednisone, cyclosporin and azathioprine. 
Rabbit antithymocyte globulin was used for the first 10 
days after heart transplantation. 
Human cytomegalovirus monitoring 
Virologic monitoring of HCMV infection was as 
follows. Heparinized blood samples for the pp65 
antigen test and DNA detection were collected weekly 
during the first month after heart transplantation and 
then every 15 days until the third month. From the 
third to the twelfth month, blood was examined 
monthly. In symptomatic patients, during the acute 
phase of HCMV infection, blood was tested twice a 
week. 
PMNL sample preparation 
PMNLs were separated by sedimentation of 3-7 mL of 
heparinized blood sample in a 6% dextran solution 
(5 vol. blood/l vol. dextran solution). Leukocytes were 
centrifuged at 2500rev/min for 10 min at room 
temperature, and the resulting pellet was washed in 
0.8% NH4Cl for 1-2 min to eliminate red blood cell 
contamination. PMNLs were then centrifuged and 
resuspended in 1 mL of phosphate-buffered saline 
(PBS), pH 7.4. Aliquots of 200 000 PMNLs were used 
for the pp65 antigen test and for DNA detection by 
PCR.  
pp65 antigen test (antigenemia) 
Aliquots of 700000 PMNLs were prepared on glass 
slides by use of a cytocentrifuge (Cytospin 2, Shandon 
Southern Products, Astmoor, UK). The PMNLs were 
fixed in 5%) formaldehyde-PBS for 10 min. After 
fixation, a permeabilization step with Nonidet P-40 
(Sigma, St. Louis, USA) was carried out before staining 
with a pool of mouse monoclonal antibodies to HCMV 
pp65 antigen ((210-Cll; Biotest, Dreieich, Germany) 
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for 45 min. After the first incubation, the slides were 
washed twice in PBS suppleniented with 1% fetal calf 
serum and then stained with fluorescein-conjugated 
F(ab’)? fragment of rabbit antimouse immunoglobulins 
(Dako, Glostrup, Denmark). Slides were rinsed twice 
in PBS, and then mounted and observed under 
fluorescent microscopy. HCMV pp65-positive PMNLs 
were counted and referred to 200 000 examined cells. 
Different levels of antigenemia (antigenic load) were 
defined as follows: low, moderate and high when the 
numbers of pp65-positive PMNLs were respectively 
6, 5-50 and >50 per 200000 examined cells “11. 
DNA extraction from leukocytes 
Aliquots of 200000 PMNLs were used for DNA 
detection by PCR.  QIAamp spin columns were 
used for DNA extraction from PMNLs, according 
to the manufacturer’s instructions (QUIAGEN GmbH, 
Hilden, Germany) [40]. 
Quantitation of HCMV DNA by PCR 
We constructed a quantitative competitive P C R  assay 
according to the method previously published by 
Zipeto et a1 [36], with some modifications. In order to 
generate a competitive non-homologous internal 
standard (IS), we used the PCR MIMICS technique for 
competitive PCR (PCR MIMIC Construction kit, 
Clontech, Palo Alto, CA, USA). The primers that we 
currently use for HCMV DNA detection in clinical 
samples are located within the translated region of the 
viral genome coding for the major immediate early 
antigen (IE1) (sequences 5’ to 3’: upstream primer 
AGA C C T  TCA T G C  AGA TCT CC,  downstream 
primer GGT GCT CAT GCA CAT TGA TC) [41,32]. 
Using the PCK MIMIC technique, we generated a pair 
of composite primers consisting of two 40-mer 
oligonucleotides whose sequence a t  the 5’ end (nt 
1-20) contained 20 bases complementary to HCMV 
primer sequences, and at the 3’ end (nt 21-40) 20 bases 
complementary to a region of a neutral-behaving 
heterologous DNA fi-agnient: a 633-bp BamHI/EtoRI 
fragment of the human v-cvB gene. After the first round 
of P C R  with the composite primers, a recombinant 
DNA molecule (DNA-MIMIC), including HCMV 
primers at its ends, was obtained that could then be 
amplified using only HCMV-specific primers. The size 
of the DNA-MIMIC molecule (340 bp) was different 
from that of the HCMV IEl product o f P C R  (263 bp). 
DNA-MIMIC was cloned into competent INVaF cells 
(TA Cloning kit, Invitrogen, San Diego, CA, USA), as 
was the HCMV amplification product, in order to 
construct a reference external standard (ES). The 
resulting two plasmids were extracted from positive 
clones using the Pure Prep Macro Plasmid purification 
system (Pharmacia Biotech, Uppsala, Sweden), and 
following linearization they were ready for a co- 
amplification PCR assay. Clinical samples (PMNLs) 
and a known amount of the ES (number of copies from 
10 to lo6) were amplified in the presence of 10’ copies 
of IS. 
A reference curve for the quantitation of HCMV 
DNA was derived from the evaluation of the ES/IS 
ratio of the hybridization signals, after PCK amplifica- 
tion, for each point of the reference curve (number of 
copies from 10 to lo6). Hybridization of the amplified 
products was performed with the DNA Enzyme 
Imniunoassay (DEIA) (Sorin, Saluggia, Italy) [30]. An 
oligonucleotide probe within the amplified region of 
HCMV DNA and a probe complementary to the IS 
were used. HCMV DNA-IS hybridization signals 
(optical densities) were calculated for each sample and 
for each concentration of the reference HCMV 
standard. A logarithmic reference curve was con- 
structed by plotting the ES/IS ratio for each standard 
point against its known concentration. The same ratio 
was calculated for each sample and used to extrapolate 
the copy number from the reference curve. Absolute 
quantitation of the samples was expressed as genome 
equivalents (GE)/200 000 PMNLs. 
All the DNA extracted from 200000 PMNLs in 
each clinical sample was subjected to DNA ampli- 
fication in 100 pL PCR reaction buffer containing 
50 mmol/L KCl, 10 nimol/L Tris-HC1 (pH 8.3). 
1.5 mmol/L MgC12, 20 nmol of dNTPs, 50 pniol of 
each primer, and 2 units of AmpliTaq (Perkin-Elmer 
Cetus, Norwalk, CT, USA). The PCR reaction was 
performed in an automated thermal cycler (DNA 
Thermal Cycler, Perkin-Elmer Cetus) for 30 cycles 
(denaturation, 94°C for 40 s, annealing, 55°C for 1 min, 
extension, 72OC for 3 min; plus 5 s of autoextension 
every cycle). Twenty microliters of each aniplified 
sample was subjected to hybridization by the DEIA 
assay. 
To prevent carryover of amplified DNA sequences 
and false-positive reactions, samples were prepared 
under a biosafety hood, in a room physically isolated 
from that in which P C R  was performed. Separate 
sets of supplies and positive pipetting devices were 
dedicated to sample preparation and to set-up reactions. 
HCMV-infected human embryonic lung fibrobl‘ist cells 
were used as positive controls. Negative controls (non- 
infected human embryonic lung fibroblast cells), and a 
reagent mixture free from DNA template as ‘(I’ DNA 
control, were used in each run. 
Diagnosis and treatment of HCMV infection 
Diagnosis of HCMV infection was determined by a 
positive result in the pp65 antigen test (2 I pp65- 
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positive PMNLs). Diagnosis of HCMV primary in- 
fection was based on virus-specific IgG seroconversion 
from negative to positive in a seronegative recipient 
(R-) before heart transplantation. In anti-HCMV 
seropositive patients (R+) before heart transplantation, 
infection was recorded as reactivation/reinfection. 
Infected patients were treated with 9-( 1,3-dihydroxy- 
2-propoxymethyl) guanine (ganciclovir) at  a dosage of 
10 mg/kg per day intravenously for 14-21 days when 
symptoms of HCMV infection appeared, i.e. when 
fever occurred in combination with any one of the 
following signs: leukopenia, thrombocytopenia. rise in 
liver enzymes or gastroenteric signs. In our series, 10 
patients experienced symptomatic HCMV systemic 
infection with mild symptoms. The most common 
clinical symptom was fever associated with leukopenia 
and/or thrombocytopenia. Eleven patients experienced 
asymptomatic HCMV infection and were not treated. 
None of the HCMV-infected patients required an 
increase of the immunosuppressive regimen due to 
acute rejection. 
Statistical analysis 
Since the pp65 and DNA values were not normally 
distributed, we compared the groups with the non- 
parametric Mann-Whitney test, and p values below 
0.05 were considered to indicate statistical significance. 
RESULTS 
Patients 
The mean time of follow-up after heart transplantation 
was 134f65 days (range: 40-301 days). Six of 21 
patients were seronegative for HCMV before trans- 
plantation, and they received a graft from seropositive 
donors (D+/R-, mismatched patients), and 15 
patients were seropositive for HCMV before surgery. 
Ten patients experienced symptomatic HCMV in- 
fection. Five of them were primary infections in 
D + / R -  mismatched recipients. The other five were 
symptomatic reactivations/reinfections in seropositive 
recipients. Ganciclovir was administered immediately 
on the occurrence of mild symptoms (fever and 
leukopenia in all 10 cases) and was discontinued when 
a 90% reduction in the pretreatment antigenic value 
was achieved in a symptomless patient (14-21 days). A 
second course of ganciclovir therapy was administered 
to two D+/K-  patients because of a high peak in the 
antigenic load (270 and 1000 pp65-positive PMNLs, 
respectively) after a first 21-day course of ganciclovir. 
Eleven asymptomatic HCMV infections occurred in 10 
D+/R+ and in one D+/R- recipients. These patients 
were not treated. 
Quantitation of HCMV DNA hy PCR 
qPCR for HCMV DNA was retrospectively performed 
on 103 pp65-antigen-tested samples. Seventy-two 
leukocyte samples were from 10 symptomatic patients, 
with a median number of seven samples available for 
each patient, while 31 were the samples available for 
analysis from the 11 asymptomatic transplanted patients 
(median number of two samples from each patient). 
HCMV DNA and pp65 detection were positive in 69 
of 103 samples (67%), while both tests were negative in 
18 samples (17%). Sixteen pp65-negative samples were 
positive by PCR,  corresponding to the early stage 
of HCMV infection and after ganciclovir treatment 
(Table 1). The overall concordance between qPCR and 
antigenenlia was 84.4% (87 samples). 
HCMV symptomatic infected patients 
Ten of 21 patients (48%) experienced a symptomatic 
HCMV infection. In seven patients, HCMV infection 
was detected within 50 days from heart transplantation, 
and in three on days 53, 56 and 143 after surgery. Table 
2 shows HCMV infection monitored by the pp65 
antigen test and HCMV DNA by qPCR. After heart 
transplantation, the mean first day of HCMV detection 
in PMNLs was 45k36 (range 20-143) by the pp65 
antigen test and 41+32 (range 20-126) by PCR. 
HCMV DNA was detected by P C R  a mean of 12 days 
prior to antigenemia (range 7-17 days) in three 
patients. In the other seven patients, the two tests were 
positive simultaneously. Before therapy, the mean 
antigenic load was 3902350 pp65-positive PMNLs, 
and HCMV DNA mean levels were 4.6 x 105f4.7 x105 
GE (range 5x104 to 10'). These data differed signifi- 
cantly from those obtained in asymptomatic patients, 
in whom the mean antigenic load was 25+12 pp65- 
positive PMNLs (p<O.OOOl) and the mean DNA level 
was l.1X1O4~2.3X1O4 GE (p<O.OOOl), as shown in 
Table 3. A single course of ganciclovir therapy caused 
a marked decrease of HCMV DNA and antigenemia 
but significant differences were observed among patients. 
Eight of 10 patients (three D+/R-  and five D + / R +  
transplants) showed a prompt response to a single 14 to 
Table 1 Comparison between quantitative PCR (qPCR) 
and pp65 antigen test: number of positive and negative 
samples (PMNLs) obtained with the two tests 
qPCR 
Total - + 
+ 69 0 69 
16 18 34 
PP65 
- 
Total 85 18 103 
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Table 2 Monitoring of HCMV symptomatic infections and antiviral treatment in 10 heart transplant patients with the pp65 
antigen test and quantitative PCK for HCMV DNA detection 
D.iy of first detection Levels at the end 
from heart transplantation Levels at therapy of therapy 
HCMV HCMV HCMV Ganciclovir: 
Patients D/R status PP65 L>NA pp65" D N A ~  p p w  DNA" days of therapy' 
1 l>+/K- 36 36 0 6 70000 0 <I0 14 
3 L>+/R+ 24 24 80 10' 5 1 OO( 1 14 
3 D+/R+ 32 21 420 50000 0 <10 14 
4 D+/R- 143 126 300 1 0" 0 2( 1 I4 
5 D+/R+ 3 1  70 12s isoono 0 <I0 14 
6 D+/R+ 3Y 39 8( 1 1 06 1 1 no 14 
7 D + / R +  34 34 95 90000 7 400(1 14 
8 D+/R- 53 53 1000 I 06 4 3000 21 
9 D+/K- 29 22 760 70000 55 50000 21 
1000 5 0  00(1 n < l o  21 
10 D+/R- 36 3h 450 10" 40 4x11,' 71 
1st course 
2nd course 
Itt course 
2nd course 
270 l(S' 1 100 2lL 
'Nuniher of pp65-positive PMNLs/300OClO PMNLs. "Number of genome equivalents/200 000 PMNLt. '10 mg/kg per day. 
Table 3 Monitoring of HCMV asymptomatic infections in 11 heart transplant patients with the pph5 antigen test and 
quantitative PCR for HCMV DNA detection 
~~ ~ 
Day of first detection from Maximum level reached 
heart transplantation during follow-up 
HCMV DNA 
HCMV HCMV percistence (days 
Patientc D/R <tatus PP65 DNA pp65" LINA" from firct detection) 
1 
2 
3 
4 
5 
tl 
7 
8 
9 
10 
11 
D+/R+ 
D+/R+ 
I>+/R+ 
D+/R- 
D + / R +  
D+/R+ 
U+/K+ 
D+/R+ 
D+/R+ 
D+/R+ 
D+/R+ 
41 
18 
100 
188 
36 
40 
45 
32 
33 
30 
47 
23 
18 
100 
188 
17 
40 
45 
32 
33 
30 
31 
30 
35 
21 
20 
20 
70 
6 
15 
4 0 
50 
20 
80 000 
4000 
1000 
200 
300u 
1000 
2000 
100 
3000 
10 o0cl 
20 no0 
NA' 
NA' 
89 
30 
70 
37 
33 
30 
31 
29 
167 
~ ~~ 
'Numbcr of pph5-positive PMNLs/?OU 000 PMNLF hNumber of genome equivalentsI200 000 PMNLs 'Not available becdue the follow- 
up IS still ongoing and HCMV DNA is ttill detectable in blood afier 105 and 57 days respectively 
31-day c ~ u r s e  of therapy (Table 3, patients 1-8). 
During treatment, their mean antigenic and DNA 
loads were 274k 31 8 pp65-positive PMNLs and 
4.3X 10'k 4.7X10' GE, respectively. The mean time to 
a 90% antigen load reduction during therapy was 13 ? 6 
days. At the end of a single ganciclovir course, in three 
patients antigeneniia and DNA were negative, in one 
patient antigenemia was absent but the DNA was still 
detectable (Table 2, patient 4), and in four patients 
antigenemia and DNA were both positive (mean 
antigenic and DNA load: four pp65-positive cells 
and 1600 GE, i.e. a >98% reduction of antigenic and 
DNA pretreatment values). N o  HCMV relapse was 
experienced by the eight recipients during their follow- 
UP. 
Before therapy, in two D+/R- patients (Table 3, 
patients 9 and 10) antigenemia was very high (760 
and 450, respectively, pp65-positive cells) and their 
pretreatment DNA peaks were 5X1O4 and lxlOh GE, 
respectively. They received a first 21-day course of 
2 8  Cl in ica l  M i c r o b i o l o g y  a n d  i n fec t i on ,  Vo lume 5 Number  1, January  1999 
ganciclovir, at the end of which a 90% reduction of the 
pretreatment antigenic load was shown (55 and 40 
pp65-positive PMNLs, respectively), but we found that 
only 28% (patient 9) and 60% (patient 10) reductions 
of DNA pretreatment values were achieved, corres- 
ponding to 5 ~ 1 0 ~  (patient 9) and to 4x  lo5 GE (patient 
10) in 200,000 PMNLs. As the patients were symptom- 
less and a 90% reduction in antigenic load had been 
achieved, ganciclovir was discontinued. After 15 and 
12 days, respectively, the two patients experienced an 
asymptomatic relapse of HCMV with a high peak 
of antigenemia (1000 and 270 pp65-positive cells) 
(6) 
0 
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+ 
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Figure 1 Graphical description of two HCMV symptomatic infections in two D+/R- patients: (a) patient 9 of Table 2; (b) 
patient 10 of Table 3. The two recipients relapsed after the first 21-day ganciclovir (GCV) course, which was discontinued 
because antigenemia dropped by >90% of pretreatment values (55 and 35 pp65-positive PMNLs, respectively). As can be 
seen, in the period in which antiviral therapy was not administered (15 days in patient 9, and 12 days in patient lo), HCMV 
DNA peaks were persistently positive, while antigenemia was slowly increasing after an apparent 90% reduction. The second 
antiviral course was administered when antigenemia reached 1000 (patient 9) and 170 (patient 10) pp65 PMNLs/200000. 
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Table 4 Comparison between the pp65 antigen test and quantitative PCR (yI'CK) in symptomatic and asymptomatic 
HCMV-infected recipients before heart transplantation 
HCMV syniptoindtic HCMV asymptomatic 
I'aranieters infection (ti = 10) infection (11=11) Statistical evaluation 
pp65: day of first detection from HT 45k36 5 5 ~ 4 ' ~  NS 
pph5: antigenic loada 390k350 25?11 p<U.(JOOl' 
qPCK: day of firqt detection from H T  41232 .51+51 NS 
DNA peakb 4 . 6 ~ 1 0 ' ~ 4 . 7 x 1 0 5  I.l~lo"+2.3xlo" p < o . o o o  1 
'Number of pphS-positive PMNLs/?OO 000 PMNLs. hNumber of genome cquivalentd200 000 PMNLs. 
' T = l b S ,  Mmn-Whitney teqt. "T=l62, Mann-Whitiiey test. 
corresponding to 5 x lo4 and 1 x 10'' GE in PMNLs 
(Table 2). They received a second 21-day course of 
ganciclovir. A 90% reduction in antigenic load took 
place at days 12 and 10 during therapy (pp65 was 
undetectable in patient 9, but one pp65-positive 
PMNL was still observed in patient 10). DNA was 
undetectable in patient 9, and 100 GEs were still 
present in patient 10. During the period in which 
ganciclovir was discontinued, we retrospectively found 
persistent high HCMV DNA levels (3x104 GE and 
1 X 10" GE in patients 9 and 10, respectively), with 
increasing levels of antigeneniia, following the first 
apparent 90% reduction. After the second 21-day 
ganciclovir course, the two patients recovered com- 
pletely and did not experience any further HCMV 
relapse. Figure 1 shows the antigenic and HCMV DNA 
levels during monitoring in patients 9 (Figure 1 a) and 
10 (Figure Ib). 
HCMV asymptomatic infected patients 
Eleven out of 21 patients (53%) experienced asymp- 
tomatic HCMV infection and were not treated. Ten 
were D + / R +  and one was D+/R-. The mean first 
day of HCMV detection in PMNLs after heart 
transplantation was 55rL.19 (range 18-188) by the pp65 
antigen test and 51+51 (range 17-188) by PCR.  
HCMV DNA was detected by PCK prior to anti- 
genernia in three patients (a mean of 17 days, range 
16-19 days). In eight patients the two tests were 
positive simultaneously. Table 3 shows the antigenic 
load and HCMV DNA levels in asymptomatic patients. 
Two parameters differed significantly between asymp- 
tomatic and symptoniatic HCMV-infected patients 
(Table 3) .  In asymptomatic patients, the highest antigenic 
load and HCMV DNA maximum levels were signifi- 
cantly lower than in symptomatic recipients: 35+ 12 
pp65-positive PMNLs (range 6-50, p<0.0001) and 
1.1 X 1 04+ 2.3X 10' GE (range 100 to 8x104, p<C).OO01). 
The mean times of HCMV antigenemia and DNA 
clearance from blood were 50 L 38 days (range 15-136) 
and 57+45 days (range 29-16?), from the first 
detection, respectively. 
Between primary and secondary infections, we 
found that the highest level of pp65-positive PMNLs 
and the highest DNA load, both parameters assessed 
before therapy in symptoniatic patients, were signifi- 
cantly different. The pp65 and the l>NA values were 
higher in primary than in secondary infections: 
583 k 303 pp65-positive cells versus 85 f~ 11 1 (p=O.O02), 
and 5 2 x  lo5 k 5.2x 10' GE versus 1.5 x 10'L 3 . 2 ~  1 Oi 
GE (p=O.O2). 
DISCUSSION 
Our data show that the quantitative determination of 
HCMV DNA by P C R  has the same trend as the 
antigenic load (pp65 antigen test detection), in synip- 
tomatic and asymptomatic and in priniary as well as 
secondary HCMV infection. HCMV DNA peaks were 
significantly higher in syniptoniatic than in asynip- 
tomatic infections, and in primary versus secondary 
infection, as was the antigenic load. These data 
completely agree with previous published observations 
on quantitative P C R  results for HCMV DNA in bone 
marrow transplants and in AIDS patients [25,37,2X] as 
well as in organ transplants "61. In  our HT patients 
we found that a DNA load of l . l ~ 1 0 4 + 2 . 3 ~ 1 0 ~  
CE, corresponding to 25rL 11 pp65-positive PMNLs, 
remained asymptomatic in 10 out of 15 D+/K+ and 
in only one out ofsix D + / R -  transplant patients. These 
data agree with published observations that the immune 
system in D + / R +  patients can more easily cope with 
HCMV infection than that in D+/R- patients [33].  
The effect of antiviral treatment was evaluated in 
10 HT symptomatic patients, and important variability 
was present. In eight of them we found a correlation 
between antigenemia, HCMV DNA levels and a 
complete response to anti-HCMV therapy. These were 
five D + / R +  and three D + / R -  recipients in whom a 
response to antiviral therapy was associated with a 
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persistent decrease (five patients) or the disappearance 
(three patients) of either pp65 antigen or DNA from 
blood. In these patients a 90% reduction in antigenic 
load was achieved in 14-21 days of therapy and 
corresponded to a >98% reduction in DNA pre- 
treatment values. During therapy in these patients, 
decreasing levels in the antigenic load were associated 
with decreasing levels of viral DNA. After a single 
ganciclovir course, low levels of antigenemia and DNA 
(four pp65-positive cells and 1600 GE) were com- 
pletely controlled without HCMV relapse in five 
patients until complete disappearance of the two markers. 
In these patients we observed a good correlation between 
a 90% reduction of antigenemia, a >98% reduction of 
HCMV DNA and a complete response to anti-HCMV 
therapy. 
In two out of five primary and symptomatic 
infected recipients, we did not achieve a 98% reduction 
in DNA load with a single 21-day ganciclovir course, 
even though we showed a 90% drop in the antigenic 
load. At that time, in these two patients the DNA levels 
only decreased to 73% and 40% of the pretreatment 
levels, suggesting retrospectively a lack of or a delay in 
response and the need for continuing antiviral therapy. 
After the first ganciclovir course, the mean pp65 
antigen and DNA load were 47 positive PMNLs and 
2.2 x105 GE, respectively. The two patients relapsed 
and a second ganciclovir course was administered. 
During the second course, we obtained a >90% 
reduction of the antigenic load over a range of 10-14 
days; at that time, DNA was undetectable in one 
patient, and in the other one a >98% reduction of the 
pretreatment value was achieved. We now think that 
ganciclovir should not have been discontinued in these 
two patients because antigenemia was still positive: even 
though it was at a moderate level, it indicated that a 
significant viral load could still be present in such 
patients. 
In our experience, a >98% reduction of DNA 
pretreatment values is required for a complete and 
sustained response to anti-HCMV therapy. Our DNA 
quantitation system suggests that more prolonged 
ganciclovir therapy should be administered to primarily 
infected patients in order to achieve a complete response 
to ganciclovir and to avoid relapses. Furthermore, a 
90% reduction in pretreatment antigenic levels may be 
a less reliable predictor of the efficacy of anti-HCMV 
therapy than DNA load, at least in primary infection, 
in which a much higher viral load and more severe 
disease are present. In these infections, a 90% antigenic 
load reduction of pretreatment values is likely to be 
insufficient for complete recovery, avoiding relapses in 
HCMV infection, because of the very high viremia. 
Thus, patients with primary symptomatic infection 
should be treated until pp65 antigen is low ( < l o  
positive cells) or negative, at which point DNA load 
should also be very low (>98% reduction from the 
Pretreatment level) or absent, as shown by the present 
data. 
These results are in agreement with published data 
on anti-HCMV therapy monitored by qPCR in bone 
marrow transplant recipients and in AIDS patients 
[28,29,31,32,34-361 Those studies also showed how 
pre-emptive therapy can be started, based on HCMV 
DNA levels, and that P C R  is the method of choice for 
early HCMV detection in those high-risk populations. 
Quantitation of HCMV DNA seems to be a more 
appropriate way of monitoring HCMV infection and 
also for deciding antiviral strategies in HT recipients, 
with particular regard to D+/R-  mismatched patients 
who are at higher risk of symptomatic HCMV 
infection. 
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